Literature DB >> 9544705

Double-cleavage production of the CTL epitope by proteasomes and PA28: role of the flanking region.

N Shimbara1, H Nakajima, N Tanahashi, K Ogawa, S Niwa, A Uenaka, E Nakayama, K Tanaka.   

Abstract

BACKGROUND: Proteasomes are known to produce major histocompatibility complex (MHC) class I ligands from endogenous antigens, and the gamma-interferon-inducible proteasome activator PA28 has been thought to play an important role in the generation of immunodominant MHC ligands by proteasomes. Several attempts have been made to show that proteasomes have the ability to yield cytotoxic T lymphocyte (CTL) epitopes effectively from model polypeptides derived from viral and intracellular proteins in vitro, but their antigen processing mechanism is poorly understood.
RESULTS: Proteasomes produce the tumour rejection antigen precursor peptide pRL1b (SIIPGLPLSL), but not pRL1a (IPGLPLSL), bound to the H-2Ld molecule, from synthetic peptides covering the CTL epitope. This double cleavage production of pRL1b by proteasomes seemed to depend on the length of the flanking regions adjacent to either end of the CTL epitope, in which their successive deletions caused the almost complete prevention of pRL1b excision. The newly identified PA28 collaborates with proteasomes for efficient production of pRL1b, by promoting not only single cleavage of all susceptible peptides, but also dual cleavage in some peptides harboring certain characteristic lengths.
CONCLUSION: The flanking regions outside pRL1b of suitable length appear to be essential for the correct CTL epitope production, possibly functioning as anchors to trap target peptides for proteasomal degradation. We propose a novel mechanism for dual-cleavage excision of immunodominant epitopes by proteasomes and PA28.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9544705     DOI: 10.1046/j.1365-2443.1997.1610359.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  12 in total

1.  A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates.

Authors:  H G Holzhütter; P M Kloetzel
Journal:  Biophys J       Date:  2000-09       Impact factor: 4.033

2.  The origin of proteasome-inhibitor resistant HLA class I peptidomes: a study with HLA-A*68:01.

Authors:  Noel García-Medel; Alejandro Sanz-Bravo; Eilon Barnea; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2011-10-03       Impact factor: 5.911

3.  Computational prediction of cleavage using proteasomal in vitro digestion and MHC I ligand data.

Authors:  Yu-feng Lu; Hao Sheng; Yi Zhang; Zhi-yang Li
Journal:  J Zhejiang Univ Sci B       Date:  2013-09       Impact factor: 3.066

4.  Proteasome allostery as a population shift between interchanging conformers.

Authors:  Amy M Ruschak; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

Review 5.  The proteasome-dependent proteolytic system.

Authors:  N Tanahashi; H Kawahara; Y Murakami; K Tanaka
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

6.  PA28 and the proteasome immunosubunits play a central and independent role in the production of MHC class I-binding peptides in vivo.

Authors:  Natascha de Graaf; Mary J G van Helden; Kathrin Textoris-Taube; Tomoki Chiba; David J Topham; Peter-Michael Kloetzel; Dietmar M W Zaiss; Alice J A M Sijts
Journal:  Eur J Immunol       Date:  2011-03-01       Impact factor: 5.532

7.  Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes.

Authors:  Paolo Cascio; Matthew Call; Benjamin M Petre; Thomas Walz; Alfred L Goldberg
Journal:  EMBO J       Date:  2002-06-03       Impact factor: 11.598

8.  Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome.

Authors:  H Furukawa; S Murata; T Yabe; N Shimbara; N Keicho; K Kashiwase; K Watanabe; Y Ishikawa; T Akaza; K Tadokoro; S Tohma; T Inoue; K Tokunaga; K Yamamoto; K Tanaka; T Juji
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

Review 9.  The proteasome activator 11 S REG (PA28) and class I antigen presentation.

Authors:  M Rechsteiner; C Realini; V Ustrell
Journal:  Biochem J       Date:  2000-01-01       Impact factor: 3.857

10.  Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing.

Authors:  Taketoshi Yamano; Shigeo Murata; Naoki Shimbara; Noriaki Tanaka; Tomoki Chiba; Keiji Tanaka; Katsuyuki Yui; Heiichiro Udono
Journal:  J Exp Med       Date:  2002-07-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.